RxDoctor Payments Data

Mia Chorney, NP

Family · Chandler, AZNPI 1255705125

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $53,750 of the $78,701 with a category attached, or 68.3%. ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) accounts for 94.3% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2022 at $33,944 and has fallen 87.2% since, to $4,328 in 2025. Among family clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$78,701in general payments, 2019–2025

Across 218 payments — averaging $361.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$74K
  • ZOLL Medical Corporation$2K
  • Novartis$272
  • Itamar Medical Inc$256
  • Medtronic$249
  • Abbott$235
  • plus $2K from 23 others

What the payments were for

  • Speaking & faculty fees$53,75068%
  • Travel & lodging$18,01123%
  • Food & beverage$6,9409%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$78,701 in reported general payments places this provider in the 95th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$35,175
Medicare patients
179
Services billed
444

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban30$33,152
Repatha SureclickEvolocumab14$21,821
Rosuvastatin Calcium104$1,575
Metoprolol Succinate115$1,446
Ezetimibe46$828
Valsartan13$489
Losartan Potassium35$480
Amlodipine Besylate73$433
Atorvastatin Calcium47$430
Lisinopril64$423
Carvedilol16$138
Pravastatin Sodium11$127
Metoprolol Tartrate16$82
Hydrochlorothiazide20$51

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$161$33,15230 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,119 family providers in Arizona.

Other family in Chandler

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →